Atara Biotherapeutics (NASDAQ:ATRA) Shares Cross Below 50 Day Moving Average of $0.73

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.73 and traded as low as $0.68. Atara Biotherapeutics shares last traded at $0.71, with a volume of 832,144 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

Atara Biotherapeutics Price Performance

The firm has a market cap of $85.33 million, a price-to-earnings ratio of -0.27 and a beta of 0.69. The stock has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.81.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in shares of Atara Biotherapeutics by 8.4% in the first quarter. Royal Bank of Canada now owns 25,962 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 2,017 shares during the period. Principal Financial Group Inc. boosted its stake in Atara Biotherapeutics by 15.1% during the 4th quarter. Principal Financial Group Inc. now owns 23,472 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 3,076 shares during the period. Lazard Asset Management LLC grew its position in Atara Biotherapeutics by 29.1% during the 4th quarter. Lazard Asset Management LLC now owns 15,386 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,464 shares during the last quarter. UBS Group AG grew its position in Atara Biotherapeutics by 1.5% during the 1st quarter. UBS Group AG now owns 249,283 shares of the biotechnology company’s stock worth $2,316,000 after purchasing an additional 3,689 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Atara Biotherapeutics by 2.9% in the fourth quarter. Millennium Management LLC now owns 139,080 shares of the biotechnology company’s stock valued at $456,000 after purchasing an additional 3,865 shares during the period. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.